Avadel Pharmaceuticals plc

NasdaqGM:AVDL 株式レポート

時価総額：US$1.0b

Avadel Pharmaceuticals マネジメント

マネジメント 基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Greg Divis

最高経営責任者

US$985.2k

報酬総額

CEO給与比率60.9%
CEO在任期間5.8yrs
CEOの所有権n/a
経営陣の平均在職期間4.9yrs
取締役会の平均在任期間6.3yrs

経営陣の近況

Recent updates

Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable

Oct 16
Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Sep 10
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On

Sep 03

Avadel Pharmaceuticals: Inflection Point Ahead

Jun 16

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Apr 02

Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang

Mar 05

Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop

Jan 28

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?

Jan 16
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?

Avadel May Continue To Outperform With Positive Launch Momentum

Jan 11

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?

Sep 22
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?

Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?

Aug 01
Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?

Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

May 03
Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

Avadel Pharmaceuticals filed for 500M mixed shelf offering

Aug 31

Avadel Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Jul 07
Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023

Jun 29

Avadel: Further Delay, But Some Light At The End Of The Tunnel

Jun 16

Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness

Mar 21

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Mar 15
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Nov 19
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Avadel Pharmaceuticals: I Am Holding

Nov 01

Avadel Pharmaceuticals, The Jazz-Killer

Aug 05

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Jul 23
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy

Jun 09

Avadel Pharmaceuticals EPS beats by $0.09

May 10

Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021

Mar 11
Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021

CEO報酬分析

Avadel Pharmaceuticals の収益と比較して、Greg Divis の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$73m

Jun 30 2024n/an/a

-US$106m

Mar 31 2024n/an/a

-US$157m

Dec 31 2023US$985kUS$600k

-US$160m

Sep 30 2023n/an/a

-US$159m

Jun 30 2023n/an/a

-US$143m

Mar 31 2023n/an/a

-US$142m

Dec 31 2022US$754kUS$561k

-US$137m

Sep 30 2022n/an/a

-US$132m

Jun 30 2022n/an/a

-US$134m

Mar 31 2022n/an/a

-US$90m

Dec 31 2021US$3mUS$545k

-US$77m

Sep 30 2021n/an/a

-US$66m

Jun 30 2021n/an/a

-US$56m

Mar 31 2021n/an/a

-US$6m

Dec 31 2020US$3mUS$520k

US$7m

Sep 30 2020n/an/a

US$16m

Jun 30 2020n/an/a

US$18m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$1mUS$472k

-US$33m

Sep 30 2019n/an/a

-US$94m

Jun 30 2019n/an/a

-US$101m

Mar 31 2019n/an/a

-US$96m

Dec 31 2018US$685kUS$417k

-US$95m

Sep 30 2018n/an/a

-US$40m

Jun 30 2018n/an/a

-US$2m

Mar 31 2018n/an/a

US$30m

Dec 31 2017US$1mUS$375k

US$68m

報酬と市場: Gregの 総報酬 ($USD 985.20K ) は、 US市場 ($USD 3.20M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Gregの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Greg Divis (57 yo)

5.8yrs

在職期間

US$985,200

報酬

Mr. Gregory J. Divis Jr., also known as Greg, has been Director of Avadel Pharmaceuticals plc since June 3, 2019 and has been its Chief Executive Officer since January 2019. Mr. Divis served as an Interim...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Gregory Divis
CEO & Director5.8yrsUS$985.20kデータなし
Thomas McHugh
Senior VP4.9yrsUS$663.14k0.084%
$ 865.4k
Richard Kim
Chief Commercial Officer3.8yrsUS$770.95k0%
$ 0
Jerad Seurer
General Counsel & Company Secretary4.2yrsデータなし0.0091%
$ 94.6k
Gregory Davis
VP of Corporate and Business Development9.3yrsデータなし0.17%
$ 1.7m
Mark Elrod
Vice President of Sales8.3yrsデータなしデータなし
Angie Woods
Vice President of People & Culture3.5yrsデータなしデータなし
Jordan Dubow
Consultant5.6yrsUS$982.54kデータなし
Jason Vaughn
Senior Vice President of Technical Operations4.9yrsデータなしデータなし
Jennifer Gudeman
Senior Vice President of Medical & Clinical Affairsno dataデータなしデータなし

4.9yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: AVDLの経営陣は 経験豊富 であると考えられます ( 4.9年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Gregory Divis
CEO & Director5.4yrsUS$985.20kデータなし
Jean-Marie Lehn
Member of Scientific Advisory Board19.8yrsデータなしデータなし
Mark McCamish
Independent Director4.9yrsUS$449.84k0.070%
$ 720.6k
Naseem Amin
Independent Directorless than a yearデータなしデータなし
Peter Thornton
Independent Director7.4yrsUS$459.84k0.086%
$ 892.8k
Christian Trepo
Member of Scientific Advisory Board19.8yrsデータなしデータなし
Patrick Couvreur
Member of Scientific Advisory Boardno dataデータなしデータなし
Eric Ende
Independent Director5.9yrsUS$452.34k0.17%
$ 1.8m
Catherine Bréchignac
Chairman of Scientific Advisory Boardno dataデータなしデータなし
Geoffrey Glass
Independent Non-Executive Chairman of the Board6.3yrsUS$482.34k0.13%
$ 1.3m
Linda Palczuk
Independent Director6.3yrsUS$452.34k0.054%
$ 563.3k

6.3yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: AVDLの 取締役会 は 経験豊富 であると考えられます ( 6.3年の平均在任期間)。